Biomerica Posts Q1 Profit Amid Sales Dip, Going Concern Doubts Persist

Ticker: BMRA · Form: 10-Q · Filed: Oct 14, 2025 · CIK: 73290

Biomerica INC 10-Q Filing Summary
FieldDetail
CompanyBiomerica INC (BMRA)
Form Type10-Q
Filed DateOct 14, 2025
Risk Levelhigh
Pages15
Reading Time18 min
Key Dollar Amounts$0.08
Sentimentmixed

Sentiment: mixed

Topics: Biomedical Technology, Diagnostics, Going Concern, Net Income, Sales Decline, Equity Financing, Cash Flow

Related Tickers: BMRA

TL;DR

**BMRA's Q1 profit is a mirage, fueled by 'other income' and stock sales, while core sales are shrinking and the 'going concern' warning screams trouble ahead.**

AI Summary

BIOMERICA INC (BMRA) reported a significant turnaround in net income for the three months ended August 31, 2025, achieving a net income of $2,000 compared to a net loss of $1,316,000 in the same period of 2024. This improvement was primarily driven by a substantial increase in other income, which rose from $56,000 in Q1 2024 to $1,123,000 in Q1 2025. Despite this, net sales decreased by 23.6% to $1,380,000 from $1,807,000 year-over-year. Gross profit, however, increased by 46.7% to $424,000 from $289,000, due to a more significant reduction in cost of sales (down 37.0%) than the decline in net sales. Operating expenses decreased slightly by 6.9% to $1,542,000. The company's cash and cash equivalents increased to $3,053,000 as of August 31, 2025, from $2,399,000 at May 31, 2025, largely due to $912,000 in net proceeds from common stock sales. However, the company still faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of approximately $53,200,000 and insufficient cash to meet operating requirements for the next twelve months.

Why It Matters

For investors, this filing presents a mixed bag: a return to profitability is a positive signal, but the significant decline in net sales and the explicit 'going concern' warning are major red flags. The company's reliance on a single key customer for 48% of net sales in Q1 2025 also introduces substantial concentration risk, which could impact future revenue stability. Employees and customers might face uncertainty given the company's precarious financial position and ongoing cost-cutting measures. The broader market for diagnostic and therapeutic products will watch to see if Biomerica can successfully execute its strategic plans and secure additional financing in a competitive healthcare landscape.

Risk Assessment

Risk Level: high — The company explicitly states, "These factors raise substantial doubt about our ability to continue as a going concern." This is supported by an accumulated deficit of approximately $53,200,000 as of August 31, 2025, and management's belief that current cash and cash equivalents of $3,053,000 are insufficient to meet operating cash requirements and strategic growth objectives for the next twelve months.

Analyst Insight

Investors should exercise extreme caution and consider avoiding BMRA stock due to the explicit going concern warning and declining net sales. Existing shareholders should evaluate their position, as the need for additional financing could lead to further dilution or unfavorable debt terms. Monitor future filings closely for concrete progress on sales growth, expense reduction, and successful capital raises.

Financial Highlights

debt To Equity
N/A
revenue
$1,380,000
operating Margin
-111.7%
total Assets
N/A
total Debt
N/A
net Income
$2,000
eps
N/A
gross Margin
30.7%
cash Position
$3,053,000
revenue Growth
-23.6%

Revenue Breakdown

SegmentRevenueGrowth
Net Sales$1,380,000-23.6%

Key Numbers

Key Players & Entities

FAQ

What was Biomerica's net income for the three months ended August 31, 2025?

Biomerica, Inc. reported a net income of $2,000 for the three months ended August 31, 2025. This marks a significant improvement compared to a net loss of $1,316,000 for the same period in 2024.

How did Biomerica's net sales change in Q1 2025 compared to Q1 2024?

Biomerica's net sales decreased to $1,380,000 for the three months ended August 31, 2025, down from $1,807,000 in the same period of 2024. This represents a decline of approximately 23.6%.

What is the primary reason for Biomerica's return to profitability in Q1 2025?

The primary reason for Biomerica's return to profitability was a substantial increase in other income, which rose to $1,123,000 for the three months ended August 31, 2025, compared to only $56,000 in the prior year's period.

Does Biomerica have sufficient liquidity to fund its operations for the next twelve months?

No, management believes that Biomerica's current cash and cash equivalents of approximately $3,053,000 as of August 31, 2025, are insufficient to meet its operating cash requirements and strategic growth objectives for the next twelve months.

What is Biomerica's accumulated deficit as of August 31, 2025?

As of August 31, 2025, Biomerica, Inc. had an accumulated deficit of approximately $53,200,000. This significant deficit contributes to the substantial doubt about the company's ability to continue as a going concern.

How much cash did Biomerica raise from common stock sales in Q1 2025?

During the three months ended August 31, 2025, Biomerica sold 258,569 shares of common stock, resulting in gross proceeds of approximately $939,000 and net proceeds of $912,000 after deducting commissions and other offering-related fees.

What is Biomerica's primary product focus?

Biomerica's primary focus is the research, development, commercialization, and regulatory approval of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), including its inFoods IBS product.

What is the concentration of credit risk for Biomerica's net sales?

For the three months ended August 31, 2025, one key customer located in Asia accounted for 48% of Biomerica's net sales. This indicates a high concentration of credit risk.

What strategies is Biomerica pursuing to address its capital needs?

Biomerica is actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity, and explore other strategic alternatives to address its capital needs and sustain operations.

What was Biomerica's gross profit for the three months ended August 31, 2025?

Biomerica's gross profit for the three months ended August 31, 2025, was $424,000. This was an increase from $289,000 in the same period of 2024, despite lower net sales, due to a more significant reduction in cost of sales.

Risk Factors

Industry Context

BIOMERICA INC operates in the healthcare and diagnostics sector. This industry is characterized by rapid technological advancements, stringent regulatory oversight (e.g., FDA), and competitive pressures from both established players and innovative startups. Companies often face challenges in product development, market adoption, and reimbursement policies.

Regulatory Implications

As a medical diagnostics company, BIOMERICA INC is subject to rigorous regulatory scrutiny from bodies like the FDA. Compliance with quality standards, clinical trial requirements, and marketing regulations is critical. Any failure to comply can result in significant penalties, product recalls, and reputational damage, impacting financial performance and market access.

What Investors Should Do

  1. Monitor customer concentration risk
  2. Scrutinize the source of 'Other Income'
  3. Assess the path to operational profitability
  4. Evaluate the going concern assessment

Key Dates

Glossary

Accumulated Deficit
The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates significant historical unprofitability for BIOMERICA INC, contributing to going concern doubts.)
Going Concern
An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (BIOMERICA INC faces substantial doubt about its ability to continue as a going concern, highlighting significant financial distress.)
Other Income
Income generated from sources other than the company's primary business operations. (A substantial increase in other income ($1,123,000 in Q1 2025 vs $56,000 in Q1 2024) was the primary driver of the reported net income turnaround.)
Cost of Sales
The direct costs attributable to the production or purchase of the goods sold by a company. (A significant reduction in cost of sales (down 37.0%) helped boost gross profit despite lower net sales.)

Year-Over-Year Comparison

Compared to the prior year's first quarter, BIOMERICA INC reported a dramatic shift from a net loss of $1,316,000 to a net income of $2,000, primarily due to a surge in 'other income'. However, this was accompanied by a significant 23.6% decrease in net sales to $1,380,000. Gross profit improved by 46.7% due to better cost of sales management. New risks include a high customer concentration (48% of sales) and continued doubt about the company's ability to continue as a going concern, despite an increase in cash from stock sales.

Filing Stats: 4,441 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2025-10-14 17:11:06

Key Financial Figures

Filing Documents

Financial Statements

Financial Statements: Condensed Consolidated Balance Sheets (unaudited) – August 31, 2025 and May 31, 2025 1 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited) – Three Months Ended August 31, 2025 and 2024 2 Condensed Consolidated Statements of Shareholders' Equity (unaudited) – Three Months Ended August 31, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows (unaudited) – Three Months Ended August 31, 2025 and 2024 4 Notes to Condensed Consolidated Financial Statements (unaudited) 5-13 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14-18 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 19 Item 4.

Controls and Procedures

Controls and Procedures 19 PART II Other Information Item 1.

Legal Proceedings

Legal Proceedings 20 Item 1A. Risks Factors 20 Item 5. Other Information 20 Item 6. Exhibits 20

Signatures

Signatures 21 i PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS BIOMERICA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) August 31, 2025 May 31, 2025 Assets Current Assets: Cash and cash equivalents $ 3,053,000 $ 2,399,000 Accounts receivable, net 1,205,000 731,000 Inventories, net 1,473,000 1,490,000 Prepaid expenses and other 168,000 255,000 Total current assets 5,899,000 4,875,000 Property and equipment, net of accumulated depreciation and amortization 120,000 135,000 Right-of-use assets, net of accumulated amortization of $ 1,305,000 and $ 1,223,000 as of August 31, 2025 and May 31, 2025, respectively 347,000 429,000 Investments 165,000 165,000 Intangible assets, net of accumulated amortization of $ 74,000 and $ 69,000 as of August 31, 2025 and May 31, 2025, respectively 223,000 228,000 Other assets 100,000 113,000 Total Assets $ 6,854,000 $ 5,945,000 Liabilities and Shareholders' Equity Current Liabilities: Accounts payable and accrued expenses $ 681,000 $ 672,000 Accrued compensation 591,000 655,000 Advances from customers 54,000 55,000 Lease liabilities, current portion 367,000 358,000 Total current liabilities 1,693,000 1,740,000 Lease liabilities, net of current portion 6,000 100,000 Total Liabilities 1,699,000 1,840,000 Commitments and contingencies (Note 6) - - Shareholders' Equity: Preferred stock, Series A 5% convertible, $ 0.08 par value, 571,429 shares authorized, none issued and outstanding as of August 31, 2025 and May 31, 2025 - - Preferred stock, undesignated, no par value, 4,428,571 shares authorized, none issued and outstanding as of August 31, 2025 and May 31, 2025 - - Preferred stock, value - - Common stock, $ 0.08 par value, 25,000,000 shares authorized, 2,815,410 and 2,546,216 issued and outstanding at August 31, 2025 and May 31, 2025, respectively 225,000 203,000 Additional paid-in capi

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing